It is estimated that while the majority of SARS-CoV2 infections in the ongoing coronavirus disease-2019 (COVID-19) pandemic are asymptomatic or have mild symptoms, hospitalizations and mortality largely occurs in patients with co-morbid conditions such as obesity, diabetes and COPD. Our understanding of the role of environmental exposures in modifying the response to SARS-CoV2 is emerging and air pollution; smoking and vaping have been associated with worst outcomes of SARS-CoV2 patients. There is a time sensitive urgent need to understand host defense mechanisms which are compromised due to environmental exposures and may increase susceptibility to SARS-CoV2 infection. This competing revision will forge collaboration with expert in SARS-CoV2 research to expand our horizon in this critical area. We will test the hypothesis of targeting a host defense pathway which is compromised in air pollution that may protect and modify the response to SARS-COV2 respiratory infection. Through the parent U grant, we have demonstrated that chronic exposure to PM2.5 has an overarching role in epigenetic reprogramming. Our studies have established that transcription factor Nuclear factor erythroid-factor 2 (Nrf2) is a key activator of anti-oxidative, anti-inflammatory, and innate immune defenses. We and others have demonstrated in human biospecimens and animal models that chronic exposure to PM2.5 causes a decline in Nrf2 activity that correlates with compromised innate immune defenses. In mice deficient for Nrf2 (Nrf2-/-), viral and bacterial infection causes oxidative stress, worsened lung inflammation, acute lung injury and greater mortality compared to wildtype mice. Genetic or pharmacological activation of Nrf2 pathway can rescue these effects. Disruption of Nrf2 pathway has been shown to cause upregulation of angiotensin-converting enzyme 2 (ACE2) which is the functional receptor for SARS-CoV2 entry into lung epithelial cells. Furthermore, hypomethylation in ACE2 gene has been demonstrated to increase ACE2 expression in immunocompromised patients. The goal for this project is to investigate the crosstalk of air pollution exposure, host defense and SARS-CoV2 infection. Preclinical testing of therapeutic efficacy of Nrf2 activators will provide proof of concept for further development a novel drug target for prevention and treatment of SARS-COV2 infection. The proposal will leverage expertise of our team on air pollution, respiratory diseases and an expert virologist with ongoing BSL-3 SARS-CoV2 research. Successful completion of this project will provide proof of concept for future studies directed towards development of a novel strategy of targeting host defense for prevention and treatment of SARS-CoV2 infection in susceptible populations.
Our understanding of the role of environmental exposures in modifying the response to SARS-CoV2 is emerging and air pollution; smoking and vaping have been associated with worst outcomes of SARS-CoV2 patients. The proposed studies will improve our understanding of how air pollution may increase our susceptibility to SARS-CoV2 infection in lungs and help develop a novel therapy for prevention and treatment.
| Casin, Kevin M; Fallica, Jonathan; Mackowski, Nathan et al. (2018) S-Nitrosoglutathione Reductase Is Essential for Protecting the Female Heart From Ischemia-Reperfusion Injury. Circ Res 123:1232-1243 |
| Ramanathan Jr, Murugappan; London Jr, Nyall R; Tharakan, Anuj et al. (2017) Airborne Particulate Matter Induces Nonallergic Eosinophilic Sinonasal Inflammation in Mice. Am J Respir Cell Mol Biol 57:59-65 |
| Gao, Lie; Zimmerman, Matthew C; Biswal, Shyam et al. (2017) Selective Nrf2 Gene Deletion in the Rostral Ventrolateral Medulla Evokes Hypertension and Sympathoexcitation in Mice. Hypertension 69:1198-1206 |
| Sussan, Thomas E; Sudini, Kuladeep; Talbot Jr, C Conover et al. (2017) Nrf2 regulates gene-environment interactions in an animal model of intrauterine inflammation: Implications for preterm birth and prematurity. Sci Rep 7:40194 |
